Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBIT: 2023-2025

Historic EBIT for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' EBIT fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 28.81%. This contributed to the annual value of -$56.6 million for FY2024, which is 12.43% down from last year.
  • Per Compass Therapeutics' latest filing, its EBIT stood at -$15.8 million for Q3 2025, which was up 24.92% from -$21.1 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' EBIT peaked at -$9.7 million during Q1 2023, and registered a low of -$21.1 million during Q2 2025.
  • Moreover, its 3-year median value for EBIT was -$15.0 million (2024), whereas its average is -$14.7 million.
  • Data for Compass Therapeutics' EBIT shows a maximum YoY plummeted of 40.69% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Compass Therapeutics' EBIT stood at -$15.4 million in 2023, then dropped by 7.67% to -$16.6 million in 2024, then declined by 29.23% to -$15.8 million in 2025.
  • Its last three reported values are -$15.8 million in Q3 2025, -$21.1 million for Q2 2025, and -$18.0 million during Q1 2025.